- HOME
- SMB·BIO
-
Bae Jo-ung rules out Korea Federation of SMEs chief race, vows to focus on ready-mix concrete industry
Bae rules out run for Korea Federation of SMEs chief, reversing 'wait-and-see' stance 'I said from the outset I would not run,' he says, signaling intent to seek another term leading ready-mix concrete federation Plans to focus on industry challenges including construction slump and on-site batch plant expansion Bae Jo-ung, chairman of the Korea Ready-Mixed Concrete Industry Cooperative Federation, said he will not run in the election for the 28th chairman of the Korea Federation of SMEs, scheduled for February next year. Instead, Bae said he intends to seek another term leading the ready-mix concrete federation and focus on addressing the survival challenges facing the industry amid a prolonged construction slump. Bae made the announcement Tuesday in a phone interview ahead of the "2026 Ready-Mixed Concrete Quality Management Core Personnel Competency Enhancement Conference," held at Hotel ICC in Daejeon. Asked whether he would enter the race for the federation's top post, Bae said, "I said from the outset I would not run." He also addressed his earlier remarks from October, when he had described his position as "wait-and-see," saying, "When I said I was watching and waiting, that was just my own private thinking." Bae said he plans to serve another term as chairman of the ready-mix concrete federation rather than pursue the Korea Federation of SMEs leadership. "There is still much left undone at the federation," he said. "Next year there are product designation issues and many complicated matters. It is quite hard for the industry to make ends meet." Behind Bae's decision to seek reelection lies the prolonged construction downturn and the financial difficulties gripping the ready-mix concrete sector. He singled out the growing installation of on-site batch plants by large construction companies as a key concern, warning that the trend could reduce supply volumes available to smaller ready-mix concrete firms. "In North Jeolla Province, there are 80 ready-mix concrete companies even though the population is under 2 million," Bae said. "The practice of construction companies installing their own on-site batch plants to produce concrete that nearby local firms could otherwise supply needs to be addressed." He added that protecting the market access of smaller ready-mix concrete companies was essential: "The industry can only survive if we stop construction companies from doing whatever they please." Bae also identified strengthening quality competitiveness as an ongoing priority for the federation. "Even though the ready-mix concrete industry is in a difficult situation, quality must be properly managed," he said. "Through education like this, we need to ensure that the products made by small ready-mix concrete companies earn a reputation for high quality." Bae currently serves as senior vice chairman of the Korea Federation of SMEs and had long been mentioned as a potential candidate for the top post. In an interview on Oct. 14, he said he was "watching and waiting" on whether to run, adding that "leading a large organization like the Korea Federation of SMEs requires experience and seasoning." He had continued to be cited as someone who had left the door open to a run, but his latest remarks make his decision not to enter the race unambiguous. The election for the next Korea Federation of SMEs chairman is set for Feb. 2. Among those currently mentioned as leading candidates are Kang Dong-han, chairman of the Korea Forging Industry Cooperative; Park Jang-seon, chairman of the Korea Printing Industry Cooperative Federation; Shim Seung-il, chairman of the Korea High Pressure Gas Industry Cooperative Federation; Lee Min-hyeong, chairman of the Jungbu Hume Pipe Business Cooperative; and Lee Jae-gwang, chairman of the Korea Electric Energy Industry Cooperative.
Nov. 10, 2026
-
Bubang Group chairman moves to buy W800m in shares to avert penny-stock delisting
Share price below 1,000 won for 12 consecutive trading days, raising delisting concern Chairman to buy 779.24 million won worth of shares from Dec. 10 Earnings improvement needed as share price stays weak despite treasury share cancellations Bubang Group Chairman Lee Dong-geon has decided to purchase approximately 800 million won ($590,000) worth of Bubang shares, as the company's stock price has closed below 1,000 won for 12 consecutive trading days — raising the prospect of a "penny stock" delisting under financial regulators' rules. According to Bubang Group, Lee plans to buy 805,000 common shares of Bubang on the open market from Dec. 10 to Dec. 21. The planned purchase, valued at approximately 779.24 million won, represents about 1.50 percent of total shares outstanding. Once completed, Lee's stake will rise from 1.93 percent to 3.43 percent. Bubang's share price closed below 1,000 won for 12 consecutive trading days from Oct. 23 through Monday. Monday's closing price was 968 won. As of 11:35 a.m. Tuesday, the stock was trading at 990 won, up 2.27 percent from the previous session, having briefly touched 1,000 won during intraday trading. Financial regulators began enforcing a rule in July requiring that any Kosdaq-listed company whose share price stays below 1,000 won for 30 consecutive trading days be designated a watch-list stock. If the price then fails to recover to 1,000 won or above for 45 consecutive trading days within the following 90 trading days, the company becomes subject to delisting. If Bubang's share price continues to stay below 1,000 won, the company will hit the 30-trading-day threshold on Dec. 3 — a week before Lee is set to begin purchases on Dec. 10. However, if the closing price recovers to 1,000 won or above before that point, the consecutive-day count will reset. Bubang has rolled out a series of measures this year to support its share price. The company canceled a total of 6,385,779 treasury shares — 3,002,620 in August and 3,383,159 in September — equivalent to about 10.6 percent of shares outstanding before the cancellations. Management has also been adding to its holdings. Vice Chairman Park Jae-soon, Bubang's chief executive, acquired an additional 20,000 shares in July and then bought 7,500 more between Oct. 30 and Wednesday. Park's total holdings now stand at 134,927 shares. A share price recovery will also require an improvement in earnings. Bubang's consolidated revenue last year fell to 319.5 billion won from 336.5 billion won the year before, while operating profit shrank to 1.8 billion won from 4.9 billion won. In the second quarter of this year, the company posted an operating loss of approximately 600 million won. "We will continue our efforts to enhance long-term corporate value and shareholder value based on responsible management," a Bubang official said. The company declined to say whether the share purchase was intended as a direct response to the penny-stock delisting rules. Analysts say Lee's planned open-market purchase of 800,000 Bubang common shares in December could provide some support for the stock price. Bubang's average daily trading volume over the past 10 trading days has been roughly 60,000 shares.
Nov. 10, 2026
-
Cutting payment deadline to 30 days could yield W21.6tr in annual economic benefits
Ministry of SMEs and Startups holds third meeting of payment innovation TF Discussion targets deadline unchanged since 1975 Annual benefits of up to 21.6 trillion won estimated from financial cost savings Direct payment system expansion also under review Cutting the legal deadline for paying small and medium-sized enterprises from 60 days to 30 days could generate annual economic benefits of up to 21.6 trillion won ($15.9 billion), primarily through reduced financial costs, according to new research. The Ministry of SMEs and Startups held the third meeting of its Large and Small Business Payment Innovation Task Force in Seoul on Tuesday, where officials discussed ways to improve payment practices for SMEs. The government has been pushing to overhaul payment practices that have remained largely unchanged for more than 50 years, pursuing measures including a shorter payment deadline and an expansion of the direct payment system. The meeting featured the presentation of research analyzing the economic impact of reducing the payment deadline. Research by Lee Jeong-hwan, a professor at Myongji University, estimates that cutting the legal deadline from 60 days to 30 days would generate annual social benefits of 13.9 trillion won based on companies subject to external audits. Expanding the analysis to include SMEs not subject to external audits raises the projected annual benefit to as much as 21.6 trillion won. The social benefits referred to in the research represent the economic gains companies would realize from receiving payment sooner, including reduced financing costs and improved asset returns. The 21.6 trillion won figure is not a direct cash transfer to businesses but an estimate of the broader economic effect of shortening the payment deadline. The study drew on financial data from 32,000 externally audited companies as of 2024. It found that subcontractors receiving payment more quickly could reduce interest expenses and improve asset returns, yielding measurable financial benefits. Shortening the payment deadline would ease the cash-flow burden on SMEs. A shorter gap between delivery and payment means companies would need to borrow less to cover operating costs. For smaller firms with limited financial reserves in particular, the timing of payment collection can directly affect business stability, underscoring the need to reform existing payment practices. The current 60-day legal deadline has been in place since 1975. Recent legislative activity — including an amendment to the Large-Scale Distribution Business Act and proposed revisions to the Win-Win Cooperation Act and the Subcontracting Act — reflects growing momentum to shorten the deadline. The Ministry of SMEs and Startups has operated the payment innovation TF since June, bringing together relevant government agencies, business groups and experts. The TF is led by the ministry's second vice minister and includes the Ministry of Land, Infrastructure and Transport, the Financial Services Commission, the Korea Fair Trade Commission, the Korea Federation of SMEs, the Korea Mid-sized Company Federation and the Korea Enterprises Federation. The TF has held five meetings in total through Tuesday's session — three plenary meetings and two working-level meetings. Discussions have focused on finding ways to effectively shorten payment periods across business-to-business transactions while minimizing the burden on the companies making the payments. The TF is also reviewing an expansion of the system under which project owners pay subcontractors directly. A recent amendment to the Framework Act on the Construction Industry strengthened direct payment requirements in the construction sector, and the TF is examining whether to extend that model to other subcontracting transactions and to the broader range of consignment arrangements. At Tuesday's third meeting, participants gathered industry feedback on the reform proposals developed so far and discussed the direction for future action. "The TF was launched to break the mold of long-entrenched payment practices between businesses and to work together on creating a trading environment where large and small companies can grow together," Second Vice Minister of SMEs and Startups Lee Byeong-gwon said. "We will work to institutionalize a transaction structure in which SMEs — the backbone of the national economy — can receive the right payment at the right time, and to ensure that structure takes root in practice."
Nov. 10, 2026
-
Ready-mix concrete industry signs quality pact with Korean Standards Association, draws 600 professionals
Korea Concrete Testing Institute hosts 2026 ready-mix quality management conference in Daejeon Industry and Korean Standards Association to jointly develop quality standards, training programs and specialist workforce Conference covers AI-assisted quality management and revisions to standard specifications The ready-mixed concrete industry has joined forces with the Korean Standards Association to advance quality management standardization and develop a skilled professional workforce. The initiative aims to strengthen the sector's ability to adopt AI-based quality management technology and respond to evolving industry standards, as the importance of quality control at construction sites continues to grow. The Korea Concrete Testing Institute, an affiliate of the Korea Ready-Mixed Concrete Industry Cooperative Federation, said it held the "2026 Ready-Mixed Concrete Quality Management Key Personnel Capacity-Building Conference" at Hotel ICC in Daejeon on Tuesday. The event drew about 600 attendees, including Korea Ready-Mixed Concrete Industry Cooperative Federation Chairman Bae Jo-ung; Korea Concrete Testing Institute Director Lee Han-baek; Korean Standards Association Chairman Moon Dong-min; and Korea Concrete Institute Chairman Hong Geon-ho, along with heads of regional ready-mixed concrete cooperatives and quality management officers and practitioners from across the country. Ahead of the conference, the federation signed an MOU with the Korean Standards Association on standardization and quality innovation in the ready-mixed concrete industry. The two organizations agreed to jointly develop and disseminate quality management standards and training programs, cooperate on certification matters, and cultivate quality management specialists. They will also share field challenges arising from certification criteria and quality management processes, and collaborate on ESG management and carbon neutrality initiatives. Ready-mixed concrete is a construction material that requires quality control from manufacturing through delivery. The National Institute of Standards and Technology of Korea revised the Korean Industrial Standard "KS F 4009 (Ready-Mixed Concrete)" — which governs the manufacturing and transport of ready-mixed concrete — on Dec. 31, 2024. Quality management in the sector is subject to this product standard as well as related benchmarks such as the standard specifications for concrete construction work. The conference featured expert lectures on topics including "Ready-Mixed Concrete Quality Management and AI," "Trends in Ready-Mixed Concrete Standard Specification Revisions," and "Understanding the Properties of Ready-Mixed Concrete Binders." Sessions focused on sharing technical information and regulatory updates that quality management personnel can apply directly on site. Commendations were also presented to individuals who contributed to quality improvement and industry development. The Korea Concrete Testing Institute said it plans to continue strengthening the industry's quality management capabilities through testing, training, technical support and research and development. "Quality management officers play a vital role in safeguarding the safety of buildings and the living environments of the public," federation Chairman Bae said. "Please uphold the basic principles of quality management and help build a ready-mixed concrete industry that earns greater trust from the people."
Nov. 10, 2026
-
Jeil Pharmaceutical's Zacubo breaks into top 10 prescription drugs
New drug for gastroesophageal reflux disease surpasses 10 billion won in monthly prescriptions two years after launch Zacubo, Jeil Pharmaceutical's new drug for gastroesophageal reflux disease, has broken into the top 10 of South Korea's ethical drug market. According to Ubist's October outpatient prescription rankings released Tuesday, Zacubo recorded 10.3 billion won ($7.6 million) in prescriptions, placing it 10th in the ethical drug market before price-flexibility measures are applied. Zacubo — which contains the active ingredient zastaprazan — is South Korea's 37th domestically developed new drug in the P-CAB (potassium-competitive acid blocker) class, developed by Onconic Therapeutics, a subsidiary of Jeil Pharmaceutical. Launched in October 2024, the drug has grown into a blockbuster within two years of its release. Analysts attribute its rapid growth to several advantages over conventional PPI (proton pump inhibitor) drugs: faster onset of action, better nighttime acid suppression through a longer half-life, and the convenience of being taken regardless of meals. In January this year, the company expanded its product lineup by launching an orally disintegrating tablet formulation for greater convenience. Earlier, in June last year, it added a gastric ulcer treatment indication and continues clinical development to secure additional indications. "Zacubo has established itself as a key treatment option in South Korea's P-CAB market just two years after launch," Jeil Pharmaceutical said. "We will continue to expand its prescription scope and enhance its value in the global market."
Nov. 10, 2026
-
Cuckoo, Cuchen battle in humidifiers as Coway expands into robots and medical devices
Cuckoo launches heated humidifier using rice cooker control technology Cuchen expands lineup with humidifiers and four new refrigerator models Coway moves into medical devices and robots; Kyung Dong Navien targets bathroom appliances Rice cooker makers are now competing in the humidifier market, a water purifier company has pushed into robots and medical devices, and a boiler manufacturer has entered the bathroom appliance space. Mid-sized home appliance companies are rolling out new product lines by leveraging the technology and retail networks built around their core products. The strategies vary: some apply proprietary technology to new categories, while others expand through original equipment manufacturing partnerships. Cuckoo launched a heated humidifier (CH-J301FW) on Tuesday, applying pressure-control technology developed for its pressure rice cookers. The product uses a pressure-free heating method that prevents internal pressure from building up, backed by seven safety mechanisms. It heats water to 100 degrees Celsius and can run continuously for up to 11 hours using a 3-liter tank. Safety features include a spill-resistant structure, a dual locking system, a low-water sensor and a child lock. The move puts Cuckoo in direct competition with Cuchen, which launched two humidifier models in September — a heated humidifier and an ultrasonic humidifier. Cuchen's heated humidifier also uses a 3-liter tank and heats water above 100 degrees Celsius, with a dual safety lock and a pressure-control valve. Both companies are drawing on heating and pressure-control expertise accumulated through rice cooker manufacturing to improve the safety and hygiene of their humidifiers. Cuchen has also entered the refrigerator market. In August, the company released four refrigerator models in three capacities — 85, 89 and 205 liters — targeting single- and two-person households, office users and consumers looking for a secondary unit. It was the first time Cuchen had offered refrigerators, extending a product lineup that already includes rice cookers, induction cooktops and food waste processors. The refrigerators are supplied through an OEM arrangement with an outside manufacturer. Coway expanded into medical devices and robots this year. In October, the company officially launched a wearable walking-assist robot developed in partnership with Wirobotics and began offering it as a rental product — the first time Coway has put a robot on its rental platform. The device weighs 1.6 kilograms and provides walking support in sync with the user's movements, with seven selectable modes for different activities such as walking outdoors and climbing stairs. In January, Coway launched a home medical device brand called Terasol and released Terasol U, a medical device for treating urinary incontinence. In April, it added Terasol P, a personal low-frequency electrical stimulator. The moves extend Coway's product range beyond water purifiers, air purifiers, mattresses and massage chairs into medical devices and robots. Notably, the company is applying its established rental sales model to both new categories. The new product lines are contributing to Coway's earnings. The company reported third-quarter consolidated sales of 1.43 trillion won ($1.05 billion) on Friday, up 13.7 percent from a year earlier. Operating profit rose 7.3 percent to 260.8 billion won. Domestic sales grew 2.0 percent to 754.9 billion won. Coway said sales of new home appliances, including food waste processors and wall-mounted air conditioners, helped drive the domestic revenue expansion. Kyung Dong Navien, a boiler specialist, is also broadening its lifestyle appliance footprint. In July, the company entered the bathroom ventilation appliance market for the first time with the launch of Navien Bathcare. The product offers four functions — dehumidification, warm air, drying and exhaust — to manage moisture, odor and temperature inside bathrooms. It extends the air quality management technology the company developed through its boiler and ventilation businesses into the bathroom space. Kyung Dong Navien followed up in September with a subscription service for Bathcare, offering regular professional maintenance and bundled discounts for customers who use it alongside existing air quality management products. The launch illustrates how the company is diversifying not only its product lineup but also its sales model. An industry official in the rice cooker sector said the overall market has been shrinking as rice consumption declines, prompting companies to use the brand recognition and trust built in that space to expand into other product categories. "We are in the early stages of these markets, but earnings are showing a noticeable improvement," the official said.
Nov. 10, 2026
-
North Korean defectors face 68% higher mortality risk than South Koreans, long-term study finds
Lancet letter analyzes shifts and limits of North Korea's 'health revolution'; researchers call for gender- and settlement-tailored care A research team led by Kim Shin-gon, a professor of endocrinology at Korea University Anam Hospital, has published a series of studies examining changes in North Korea's health care system and the long-term health of North Korean defectors, building an evidence base for reducing health disparities on the Korean Peninsula and guiding future inter-Korean medical cooperation. The team published a letter in The Lancet on North Korea's "health revolution" and shifts in its medical system, and a separate nationwide study in the International Journal for Equity in Health comparing long-term mortality risks between defectors and South Korean residents. Earlier, in the August 2026 issue of the Journal of Internal Medicine, the team reported that North Korean defectors face a roughly 13% higher cancer risk than South Koreans overall — and about 31% higher among men. That study highlighted the need for tailored cancer prevention and management that accounts for both the pre-migration environment and lifestyle changes after resettlement. The Lancet letter, titled "North Korea's health revolution in its 2026 medical journals," involved researchers Lee Yo-han, Choi Hyun-gyu, Kim Young-hoon and Kim Shin-gon. The team analyzed editorials from the second 2026 issues of nine North Korean medical journals, examining the policy direction and structural limitations of the "health revolution" Pyongyang is pursuing. Kim Shin-gon and colleagues had previously published a letter in The Lancet in 2016 — "A peek into the Galapagos of the medical research field" — drawing attention to the isolation and methodological limitations of North Korean medical research. The new letter revisits that decade-old concern, looking again for signs of change within North Korea's health care ecosystem even as its insularity persists. Alongside this research, the team operates NKmedline, a platform that monitors North Korean health policy and medical research in real time. NKmedline (https://nkmedline.kr) continuously tracks trends in North Korean health policy and medical research, building an information base to understand changes and limitations in the North's medical system and to prepare for future exchange and cooperation. According to the analysis, North Korean medical journals repeatedly emphasized digital health management systems, telemedicine, emergency medical networks, health information systems for women and children, and AI-assisted clinical decision support in traditional Korean medicine. These priorities were linked to the "Local Development 20×10 Policy" — a plan to improve facilities and living conditions in 20 cities and counties each year — as well as the construction and modernization of city and county hospitals. The researchers interpreted this as a signal that North Korea is pursuing selective modernization and informatization despite its prolonged isolation. However, policy emphasis does not prove actual improvement in medical services. The researchers said that compared with the top-down push focused on hospital construction and facility modernization, structural reinforcement of community-level primary care and the traditional household doctor system was not sufficiently evident. They also said the strong emphasis on pharmaceutical self-sufficiency and the development of homegrown traditional remedies suggests that drug supply instability may be a chronic constraint rather than a temporary problem. North Korean medical journals have limitations as sources for verifying epidemiological data or health outcomes, but they can serve as an important window into policy priorities and on-the-ground implementation constraints. The researchers said the field should track both change and vulnerability rather than focusing solely on North Korea's modernization ambitions or assuming persistent backwardness. Future cooperation, they added, should be prepared with an eye toward the conditions under which the health system actually functions — including primary care and drug supply — rather than concentrating only on hospital construction and equipment provision. The team is also continuing research that compares the health of defectors — already members of South Korean society — with that of South Korean residents. A study published in the International Journal for Equity in Health, titled "Sex-specific long-term mortality inequities among North Korean refugees resettled in South Korea: a nationwide matched cohort study," analyzed differences in long-term mortality risk by sex and length of settlement. The study was supported by the Inter-Korean Health and Medical Education Foundation and the Patient-Centered Outcomes Research for Optimal Health Care (PACEN) program. The team linked National Health Insurance Service data from 2002 to 2022 with national death records, comparing 26,123 adult North Korean defectors with 1,300,144 South Korean residents matched by sex, birth year and study entry year. The median follow-up period was 10 years. After adjusting for comorbidities and medication use, male defectors faced an overall mortality risk 68% higher than South Korean men — a gap that did not narrow appreciably over the follow-up period. By cause of death, the risk of infection-related mortality was 2.97 times higher, injury- and trauma-related mortality 2.04 times higher, cancer mortality 1.45 times higher, and cardiovascular disease mortality 1.39 times higher. Women showed a different pattern. In the first six years after resettlement, female defectors had an overall mortality risk 19% lower than South Korean women, but that early advantage weakened over time. Across the full follow-up period, the overall mortality risk for female defectors was not statistically significantly different from that of South Korean women. Infection-related and injury- and trauma-related mortality risks remained elevated among women as well, at 1.70 times and 1.44 times higher, respectively. The research team said that integration into a national health insurance system alone may not be enough to close long-term health gaps. Pre-migration malnutrition and limited access to medical care, experiences during the escape and transit through third countries, and socioeconomic conditions after resettlement all need to be considered together. The team noted, however, that as an observational study, the research cannot establish causal relationships for individual factors, and did not fully assess the effects of lifestyle, mental health, housing and employment. Kim Kyung-jin, the study's lead author, said health support for North Korean defectors must extend beyond post-arrival screenings and early resettlement assistance to encompass long-term health management. "For men, given their consistently elevated mortality risk, early detection and management of chronic diseases should be strengthened," Kim said. "For women, the lower mortality risk in the early settlement period should not be a reason for complacency — long-term changes need to be monitored." Kim added that because infection- and injury-related mortality risks were elevated in both men and women, care must be continuous from prevention through treatment. "An integrated approach that addresses their social vulnerabilities alongside medical support is needed," Kim said. The two lines of research the team is pursuing — tracking changes in North Korea's health care system and monitoring the health of defectors already living in South Korea — are meant to work in tandem. By reading policy direction and implementation limits through North Korean medical journals, and by analyzing the health burdens accumulated under different conditions and the changes that follow resettlement through long-term defector health data, the team aims to lay the groundwork simultaneously for future inter-Korean health cooperation and domestic health equity policy. Kim Shin-gon said that while inter-Korean relations are at an extreme low, the value of respecting life — the starting point of health care — cannot change. "Consistently monitoring the health of North Koreans and North Korean defectors is both a humanitarian obligation and a task that must continue from the perspective of health security — protecting the health of all of us," Kim said. Kim added that defectors are already members of South Korean society and "precious neighbors who prompt us to think about the health challenges of both Koreas from within our own community." Examining how people with similar genetic backgrounds develop different patterns of health and disease after living in different environments is important medical work, Kim said. "It can be a paradox that transforms the national pain of division into medical value for disease prevention and the protection of life." Kim also said that even if the door to exchange is closed because of the political situation, research and preparation must not stop. "We will continue monitoring North Korean health trends through NKmedline and tracking the long-term health of North Korean defectors, building the evidence needed for effective health care cooperation and a health policy that leaves no one behind," Kim said.
Nov. 10, 2026
-
'Raw Core Nutrition' puts whole fruits and vegetables back at the center of the plate
Three Korean nutrition societies present new dietary strategies linking whole-food consumption to cancer prevention, healthy aging and blood sugar control A nutritional approach that prioritizes eating vegetables and fruits in their natural form — rather than taking separate vitamins or antioxidant supplements — is drawing growing attention in South Korea. Known as "Raw Core Nutrition," the concept emphasizes a food's inherent structure and the synergistic interaction of its many nutrients over any single isolated compound. A series of research findings presented at three domestic nutrition conferences has positioned it as a new strategy for healthier eating, with links to cancer prevention, extended healthy lifespan and blood sugar management. According to the Korea Food Communication Forum, Jo Jin-a, a professor in the Department of Food and Nutrition at Chungnam National University, introduced Raw Core Nutrition at the Korean Society of Food Science and Nutrition's international conference on Oct. 29 as a nutritional framework that places vegetables and fruits at the core of the diet. The concept values real food, minimal processing and whole foods — underscoring that what people eat and in what form matters just as much as how much of any given nutrient they consume. Jo said attention should be paid to the "food matrix" — the way dietary fiber, vitamins, polyphenols, flavonoids and other compounds in vegetables and fruits work together within the food's physical structure. The share of Korean adults consuming 500 grams or more of vegetables and fruits per day has fallen from 38.6 percent in 2015 to 24.4 percent in 2024, meaning three in four adults fall short of that threshold. At the same conference, Jeon Sin-young, a professor in the Department of Food and Nutrition at Soonchunhyang University, presented research linking five daily servings of vegetables and fruits to lower mortality and reduced frailty risk. Choi Jeong-hwa, a professor in the Department of Food and Nutrition at Keimyung University, said consuming a variety of vegetables and fruits in whole-food form is more important than supplementing with specific antioxidant nutrients, noting that some antioxidant supplements have not been shown to deliver the same health benefits as whole vegetables and fruits. Kang Min-ji, a professor in the food and nutrition program at Duksung Women's University, introduced a practical approach: eating a colorful variety of vegetables and fruits and supplementing any shortfall with "Raw Core Juice." The juice is made by cold-pressing three or more raw vegetables and fruits together to preserve as many phytochemicals, vitamins, minerals and other complex nutrients as possible. A representative example is KCA juice — pressed from kale, celery and apple — which keeps sugar content low by increasing the proportion of vegetables. Links to cancer prevention were also presented. At the Korean Cancer Prevention Society's international conference on Nov. 3, Shin Da-yeon, a professor in the Department of Food and Nutrition at Ewha Womans University, said a meta-analysis of 95 studies found that each additional 200 grams of daily vegetable and fruit intake was associated with roughly a 3 percent lower overall cancer risk. The association held up to about 600 grams per day. Shin proposed several practical steps under Raw Core Nutrition: eating raw vegetables every day, consuming cruciferous vegetables such as broccoli and cabbage raw by chewing or chopping them, and drinking cold-pressed juice fresh. The aim is to preserve as fully as possible the wide range of bioactive compounds found in vegetables and fruits. On Friday, the Korean Community Nutrition Society's autumn academic conference featured research on the blood sugar effects of vegetable-centered cold-pressed juice. A research team led by Kwak Jeong-hyeon, a professor in the Department of Food and Nutrition and Food Engineering at Inje University, tested 20 healthy adults and found that drinking a cold-pressed juice of celery, cabbage, kale and lemon 30 minutes before eating white rice lowered peak blood glucose concentration by an average of 15.87 mg/dL compared with drinking water. Kwak said the findings suggest that consuming vegetable-centered cold-pressed juice before meals may help blunt post-meal blood sugar spikes, but added that long-term effects require further verification. Bae Yun-jeong, a professor in the food and nutrition program at Korea National University of Transportation, said hands-on education tailored to different life stages is needed to boost vegetable and fruit consumption. Programs combining education and practical training for youth and middle-aged adults showed significant improvements in awareness of recommended daily intake and in participants' sense of self-efficacy, highlighting the importance of building real-world skills. Researchers said the core of Raw Core Nutrition lies not in relying on any single nutrient or food but in building the habit of eating vegetables and fruits in sufficient variety and quantity. They said vegetables and fruits should anchor the daily diet, with vegetable-centered Raw Core Juice serving as a practical supplement to fill gaps when whole vegetable and fruit intake falls short. At a recent Korean Society of Food Science and Nutrition conference, Duksung Women's University professor Kang Min-ji introduced a practical approach to eating a colorful variety of vegetables and fruits and using Raw Core Juice to make up any shortfall.
Nov. 10, 2026
-
Korean biotech first to confirm immune memory can prevent cancer recurrence, new tumor formation
MedPacto demonstrates effect of anticancer drug candidate MP010, findings published in Cancer Cell A Korean biotech company has become the first in the world to demonstrate that immune memory can prevent cancer — not only stopping recurrence but also blocking tumors that have not yet developed. MedPacto announced Tuesday that it confirmed this effect through preclinical research on MP010, its next-generation anticancer drug candidate. MP010 selectively binds to extra domain-B fibronectin (EDB-FN), a protein overexpressed in the tumor microenvironment (TME) of various solid cancers. At the same time, it targets TGF-β, a signaling molecule that enables cancer cells to evade the immune system and spread. Unlike conventional systemic TGF-β inhibition approaches, MP010 selectively targets the area surrounding the tumor, minimizing effects on the rest of the body while delivering a potent anticancer effect, the company said. The research also demonstrated that by inducing long-term immune memory, the drug can guard against both the recurrence of treated cancers and the development of entirely different cancer types. MedPacto said that when MP010 was administered to animal models of three types of treatment-resistant malignant pancreatic cancer, cure rates of 75.0 to 87.5 percent and a long-term survival rate of 87.5 percent were observed. "In particular, when the same cancer cells were transplanted into animal models that had been completely cured of pancreatic cancer, no tumors developed in any of the subjects," the company said. The company added that when cells from a different type of pancreatic cancer, lung cancer or bladder cancer were transplanted, more than 80 percent of subjects showed no tumor development. A paper summarizing the findings was selected as the front cover article of the November issue of Cancer Cell, one of the world's most prestigious oncology journals. Cancer Cell carries an impact factor of 56.1, placing it on par with Nature and Science. Kim Sung-jin, chairman of MedPacto and the lead researcher, said cancer cells secrete TGF-β to neutralize the immune system and reshape their surrounding environment to favor tumor growth and protection. "This research confirmed that suppressing TGF-β around the tumor can achieve complete remission and produce lasting immune effects," Kim said. The findings are significant as the first research to show that even if the "seed" — the cancer cell — carries diverse genetic mutations, changing the surrounding "soil" can enable treatment and prevent recurrence. MedPacto Chief Executive Woo Jeong-won said the study demonstrates the potential for TGF-β inhibitors to be developed into broad-spectrum anticancer drugs through new possibilities in immune memory research. "We expect MP010 to lead a new medical paradigm in which the power of immunity can defend against cancers that have yet to develop," Woo said. MedPacto is completing toxicity studies in preparation for an investigational new drug (IND) application, with plans to conduct clinical trials in South Korea and the United States targeting IND approval in early next year.
Nov. 10, 2026
-
MDS Tech adds physical AI to its embedded solutions lineup
Company showcases AI computing, vision/sensing, connectivity and security solutions Embedded solutions company MDS Tech is positioning physical AI solutions as its next growth engine. The move builds on more than 30 years of accumulated embedded technology expertise and domestic robot development experience. The company said Tuesday it will use that foundation to help customers adopt physical AI technology and bring products and services to market. MDS Tech has assembled a physical AI solutions portfolio spanning AI computing, vision and sensing, data connectivity, and system security. It has already signed a contract to supply a "Jetson full package" — comprising Nvidia Jetson modules, systems and sensors — to a domestic company's humanoid home robot development project last month. The company showcased these solutions at Robo World 2026, held last week at Kintex in Goyang, Gyeonggi Province, sharing a booth with domestic and international technology partners including Nvidia. Physical AI refers to AI that perceives real-world information, makes decisions and translates them into physical actions — a capability that requires the seamless integration of computing platforms, sensors, communications and control technologies. "We propose system configurations needed for autonomous driving robot development, with a focus on inter-technology connectivity," a company official said. "We will expand into robotics, humanoid robots and intelligent manufacturing to grow our physical AI business into a new engine of growth."
Nov. 10, 2026
-
WuXi AppTec removed from Pentagon's 'Chinese military company' list
Court injunction leads to removal from 1260H list five months after designation Regulatory risk eases ahead of December 'biotechnology concern' determination Pentagon warns relisting remains possible based on additional grounds The US Department of Defense has removed Chinese biotech contract development and manufacturing organization WuXi AppTec from its list of "Chinese military companies" under USFKI 5200.08, about five months after the firm was added to the roster in June. The move is expected to ease the regulatory burden on WuXi AppTec as the US government prepares to finalize its list of designated biotechnology concerns in December. The Pentagon announced the removal through a Federal Register notice Monday (local time), saying the deletion of WuXi AppTec from the 1260H list of Chinese military companies operating in the United States took effect Thursday. The decision follows a preliminary injunction granted by the US District Court for the District of Columbia. The Defense Department had added WuXi AppTec to the 1260H list in June — alongside Alibaba, Baidu and BYD, among a total of 188 companies — citing the firm's indirect ownership by China's State-owned Assets Supervision and Administration Commission and alleged ties to the People's Liberation Army. WuXi AppTec responded by filing a lawsuit against the Defense Department on June 11, arguing the designation did not meet the applicable legal standards and seeking its removal from the list. A court granted the company's motion for a preliminary injunction on Aug. 7, paving the way for the formal removal announced this week. However, the Pentagon said the decision was made without prejudice, meaning it does not prevent the department from relisting WuXi AppTec based on additional or supplementary grounds — leaving open the possibility of a future redesignation. Industry observers say the removal spares WuXi AppTec an immediate threat to its business operations. Companies on the 1260H list are barred from entering into direct contracts with the Defense Department, and starting in 2027, indirect purchases through third parties will also be prohibited. Particularly significant is the link between the 1260H list and the Biosecure Act, passed in December last year, which restricts US government procurement and contracting with designated "biotechnology concerns." Companies on the 1260H list are included in that category. The White House Office of Management and Budget is expected to publish its final list of biotechnology concerns before Dec. 18 — the first anniversary of the law's enactment — making the court's decision a closely watched development in the industry.
Nov. 10, 2026
-
Seoul St. Mary's Hospital: Denosumab beyond 1 year raises jaw necrosis risk in bone-metastatic prostate cancer
Analysis of 3,307 patients finds risk rises after 13 months No added fracture-prevention benefit seen beyond 1 year, study says Prostate cancer patients with bone metastases who receive the bone-protective drug denosumab for more than a year face a significantly higher risk of jaw bone necrosis, according to new research. A research team at the Catholic University of Korea College of Medicine said Tuesday it had published findings from an analysis of side effects and treatment outcomes based on denosumab administration duration in 3,307 patients with castration-resistant prostate cancer and bone metastases. The research involved Choi Su-in, professor of clinical pharmacology at Seoul St. Mary's Hospital; Kim Seo-ri, professor of hematology-oncology at Bucheon St. Mary's Hospital; and Jeong Seung-pil, a researcher at the Catholic University of Korea PIPET Data Science Division. Denosumab is a treatment that reduces skeletal complications — including fractures and spinal cord compression — in patients whose cancer has spread to the bones. It works by suppressing the activity of osteoclasts, the cells responsible for breaking down bone tissue. However, prolonged use can inhibit the bone regeneration process, potentially causing necrosis of the jaw bone. Patients may also experience impaired healing of the jaw following dental procedures such as tooth extractions. The research team analyzed national claims data from the Health Insurance Review and Assessment Service covering 2009 to 2024, dividing patients into three groups based on denosumab duration: six months or less, seven to 12 months, and 13 months or more. The average patient age was 72.6. The three-year cumulative incidence of jaw necrosis was 3.3 percent among patients treated for seven to 12 months, but rose to 12.2 percent — roughly 3.7 times higher — among those treated for 13 months or more. That translates to approximately one in eight patients developing jaw necrosis when treatment extended beyond 13 months. By contrast, the rate of skeletal complications such as fractures and spinal cord compression was about 4 percent in both groups. The findings suggest that extending denosumab treatment beyond one year does not provide additional protection against skeletal complications. Total duration of treatment was more closely associated with the risk of side effects than the dosing interval. The disadvantage of long-term use was particularly pronounced in patients under 70, and those with a history of tooth extraction faced an even higher risk of jaw necrosis. "We minimized this bias by virtually assigning all patients to three treatment strategies and comparing them as in a randomized clinical trial," Choi said. "We were able to present evidence from nationwide data showing that the balance of benefits and risks shifts at the one-year mark." However, the researchers said the findings should not be interpreted as a call to discontinue denosumab unconditionally. Stopping the drug can trigger a rebound effect in which bone breakdown accelerates rapidly, they said, making careful, patient-specific judgment necessary. "Jaw necrosis is a complication that significantly impairs eating and quality of life, and dental care is particularly important for patients with a history of tooth extraction," Kim said. "Dental and bone risks must be assessed together, and decisions on adjusting the dosing interval should be made carefully on a case-by-case basis." The findings were published in the Oct. 21 issue of the international journal JAMA Network Open. Meanwhile, Seoul St. Mary's Hospital said in August it had reached a cumulative total of 200 lutetium-177 prostate-specific membrane antigen (PSMA) nuclear medicine treatments for patients with metastatic prostate cancer — a milestone achieved across 84 patients since the hospital became the first in South Korea to introduce the treatment in November 2020.
Nov. 10, 2026
-
Kolmar Korea wins CES best innovation award in beauty tech for 2nd consecutive year, a world first
AI-powered custom lip system ChromaFlow wins best innovation award in beauty tech and innovation award in AI LumiJet Pro AI skin-care device also takes innovation award in AI category Kolmar Korea has become the first company in the world to win the best innovation award in the beauty tech category at CES for two consecutive years, the cosmetics manufacturer announced Tuesday. The company said its AI-powered personalized lip manufacturing system ChromaFlow was named the best innovation award winner in beauty tech and also received an innovation award in the AI category at CES 2027, which runs from Jan. 6 to Jan. 9 (local time) in Las Vegas. A second entry, the AI skin-care device LumiJet Pro, also earned an innovation award in the AI category. With both submissions recognized, Kolmar Korea will take home a total of three awards. The CES best innovation award goes each year to the highest-scoring product among all innovation award winners. The beauty tech category was established in 2025, with Samsung Electronics taking the inaugural best innovation award. Kolmar Korea became the first beauty company to win the honor last year and has now claimed it for the second consecutive year. According to the Consumer Technology Association, a record roughly 4,000 entries were submitted for CES innovation awards this year — a 10 percent increase from the previous year — with AI, digital health and robotics accounting for 25 percent of all submissions. Winners are selected by engineers, designers and industry experts who evaluate entries on innovation, functionality and design. ChromaFlow was developed to let users replicate on their own lips the exact lip color worn by an influencer in a video. When the device is pressed against the lips, an AI optical sensor analyzes the user's lip condition and blends seven color cartridges to produce a custom lip product in under a minute. Conventional lip products can look different on each person depending on natural lip color and skin tone, even when the same shade is used. ChromaFlow overcomes this limitation by having AI calculate the optimal color-mixing ratio for each individual's lip color. The device features a translucent body so users can watch the color-blending process as it happens. LumiJet Pro uses AI to analyze skin condition and deliver active ingredients precisely to where they are needed. The device applies "NanoJet" technology, which scans areas affected by skin trouble or pigmentation and fires ultra-fine particles loaded with active ingredients at high speed. A second technology called "Point-to-Field" then activates: when light of a specific wavelength is applied, the particles inside the skin break down and the active ingredients spread to the surrounding tissue. Kolmar Korea also developed the proprietary nano-particle formulations used in the device. The recognition is significant because it reflects Kolmar Korea's push to expand beyond its traditional cosmetics manufacturing business into AI-driven beauty tech. By extending AI's role from analyzing individual skin conditions and colors all the way to producing customized cosmetics on demand, the company is building a new competitive edge that bridges research and development with manufacturing. Going forward, Kolmar Korea plans to build a beauty tech data platform anchored by three products: CAIOME, an AI scalp-diagnosis solution; a scar beauty device that treats and conceals blemishes with makeup; and ChromaFlow. The company intends to connect AI models across each category into a single integrated system covering everything from skin diagnosis and cosmetic formulation design to manufacturing. "We will advance our beauty tech platform on the strength of accumulated data and lead the global beauty tech market," a Kolmar Korea official said. Meanwhile, Kolmar Korea will set up a booth at the Venetian Expo in Las Vegas during CES 2027 to showcase ChromaFlow and LumiJet Pro.
Nov. 10, 2026
-
Hanssem's Q3 operating profit plunges 76.5%, but 14-quarter streak holds
Sales fall 19% to 357.6 billion won; operating profit shrinks to 1.6 billion won Housing slowdown, rising raw material costs and merger expenses weigh on earnings Cumulative operating profit through Q3 reaches 23 billion won, up 47.8% on-year Hanssem's operating profit for the third quarter fell 76.5% from a year earlier, as a slowdown in housing transactions, rising raw material costs and one-time expenses from a subsidiary merger combined to squeeze margins. The company said it nonetheless maintained an operating profit for the 14th consecutive quarter. Hanssem disclosed Monday that it posted consolidated sales of 357.61 billion won ($263 million) and operating profit of 1.61 billion won in the third quarter. Sales fell 19.0% and operating profit dropped 76.5% from the same period last year. Compared with the second quarter, sales declined 14.3% and operating profit fell 85.7%. The operating profit margin slipped to about 0.5% in the third quarter from roughly 1.6% in the same period last year. Cumulative operating profit through the first three quarters reached 22.97 billion won, up 47.8% from a year earlier. Cumulative sales over the same period came to 1.17 trillion won, down 12.6%. Hanssem said earnings were hurt by a drop in home sales transactions stemming from high interest rates and tightened lending regulations, as well as rising raw material costs linked to Middle East tensions. The company also noted that the Chuseok holiday at the end of September and a major discount event in October pushed some business-to-consumer sales into the fourth quarter. In the business-to-business segment, one-time costs arose from the absorption merger of subsidiary Hanssem Nexus. Hanssem completed the merger on July 31, and expenses including taxes, legal fees and accounting advisory fees were reflected in third-quarter operating profit. To improve earnings, Hanssem has been expanding sales of higher-margin products. In its Rehouse segment, the company launched new products including the "Euro 500" and the second-generation bathroom line "Easy Bath 7." The home furnishings segment also introduced new items such as the "Timeless" and "Knob" recliners, the "Swive" sofa and a "Kids Mattress" for infants and toddlers. In the B2B segment, Hanssem plans to use the Hanssem Nexus merger as a springboard to strengthen its push into the mid-to-high-end interior market. The company intends to expand beyond its existing residential special-sales business into major reconstruction complexes in Seoul and the Greater Seoul area, as well as the residence and office furniture markets. The merger is also expected to cut overlapping operating costs and consolidate sales and construction teams. Hanssem plans to pursue an earnings recovery starting in the fourth quarter. The company aims to convert consumer demand carried over from the third quarter into sales through its large-scale discount event "Ssaem Festa" and a back-to-school student room promotion, while also expecting cost savings from the Hanssem Nexus merger to take effect. "In the third quarter, we maintained profitability for 14 consecutive quarters despite ongoing domestic and external uncertainties," a Hanssem official said. "In the fourth quarter, we will work to absorb the deferred consumer demand through major promotions and push for an improvement in earnings."
Nov. 10, 2026
-
Dasco signs W32.4b solar power management contract
Long-term operations contract with Sindasan Energy covers 21.5 years Deal runs from Jan. 2028 to June 2049, equivalent to 11.85% of last year's sales Gangjin-gun solar project to be managed with no advance payment Dasco has signed a 32.4 billion won ($23.9 million) contract to manage and operate a solar power project over 21 and a half years. The company disclosed on Monday that it signed the "Sindasan Energy Solar Power Project Management and Operations" contract with Sindasan Energy, valued at 32.38 billion won. The amount equals 11.85 percent of Dasco's consolidated sales of 273.1 billion won last year. Under the agreement, Dasco will oversee management and operations of a solar power project in the Sinjeon-myeon area of Gangjin-gun, South Jeolla Province. The contract runs from Jan. 1, 2028, to June 30, 2049 — a total of 21 and a half years from the scheduled commercial operations start date. Payment will be made after each service billing, with no down payment or advance payment required. Because the total contract value represents service fees accruing over the long term, actual sales will be recognized incrementally in line with the project's operating schedule. Dasco is primarily engaged in manufacturing road safety facilities and building materials. The contract secures a long-term operations role for the company in the solar energy sector.
Nov. 10, 2026
-
South Korean probiotic maker tops Denmark pharmacy market with home-grown strains
Cell Biotech's Gimpo factory leads Denmark's pharmacy market with proprietary strains and patented dual-coating technology Smart 24-hour controls and AI sorting drive production as the company weighs facility expansion to meet export demand A Phase 1 trial with Seoul National University Hospital advances a colorectal cancer drug candidate, signaling a push into biopharmaceuticals The moment the airlock door to the fermentation wing swung open, a warm, yeasty aroma — somewhere between freshly baked bread and steaming makgeolli mash — filled the air. The scent comes from the grain- and yeast-based nutrient medium used to cultivate lactic acid bacteria. Beyond the door, rows of large fermentation tanks hummed steadily. On Wednesday, at Cell Biotech's production base in Wolgot-myeon, Gimpo, Gyeonggi Province — about an hour's drive from Seoul — the tanks were churning out more than 100,000 trillion lactic acid bacteria a day through 10 metric tons of culture fluid. Every finished probiotic product Cell Biotech makes carries a proprietary strain identification number, known internally as a Strain Number. The strains were isolated directly from sources including the fecal matter of exclusively breastfed newborns and traditional kimchi. All are 100 percent Korean-origin strains, including 11 varieties listed under the US Food and Drug Administration's Generally Recognized As Safe, or GRAS, designation — the agency's highest safety certification. The unique registration system, which transparently documents each strain's origin and safety profile, sets the company apart from contract manufacturers that simply blend imported raw ingredients. "We cultivate Korean-origin strains isolated from traditional fermented foods and the fecal matter of Korean newborns at a scale of more than 100,000 trillion organisms a day," said Choi Seon-gu, Cell Biotech's fermentation team leader. "The entire microbial fermentation process is controlled in real time around the clock through a smart factory system, which keeps quality consistent." Inside the fermentation vessels, conditions are kept precisely at 37 degrees Celsius — the optimal growth temperature for lactic acid bacteria — in an anaerobic, oxygen-free environment. Smart sensors continuously adjust acidity levels in real time to prevent the bacteria from producing excess lactic acid and dying off prematurely. Once cultivation is complete, the bacterial mass passes through a high-speed continuous centrifuge, concentrating it into a thick, yogurt-like form before feeding directly into the company's core proprietary process: Dual Coating. Dual Coating is a patented technology that first wraps live lactic acid bacteria in a protein layer to withstand strong acidity, then applies a second polysaccharide layer to boost resistance during processing and storage. The capsule is designed to stay tightly sealed in the stomach's acidic environment — pH 2 to 3 — and in bile, protecting the bacteria until they reach the neutral environment of the intestine at pH 6 to 7, where the coating gradually dissolves. The technology raises intestinal survival rates by up to 221 times compared with standard coated probiotics, and the clinical results are officially printed on product packaging in Singapore and several European markets. The live bacteria then undergo freeze-drying — a roughly 96-hour process that sublimates moisture from the frozen cells — yielding a pure white powder. The entire production chain, from strain isolation through cultivation, harvesting, freeze-drying, coating and finished-product packaging, is completed within a single facility. Cell Biotech has maintained this one-stop integrated manufacturing philosophy since its founding in 1995. The finished-product factory, where formulation and packaging take place, is controlled as a positive-pressure cleanroom rated at ISO Class 8 or cleaner. Workers must pass through a relay differential-pressure chamber and an air shower before entering the production floor. Along one side of the tablet line, an AI vision sorter — introduced seven years ago — scans hundreds of probiotic capsules per minute, detecting microscopic cracks and specks with close to 100 percent accuracy. Rather than standard plastic PTP blister packs, the line uses strip packaging with a special aluminum layer on both sides, keeping bacteria viable even in the hot, humid tropical climates of Southeast Asia and similar markets. That production infrastructure has become the foundation of Cell Biotech's international push. In Denmark — home to global ingredient giants such as Chr. Hansen and long considered the birthplace of modern probiotics — Cell Biotech's Duolac brand held a 46.6 percent share of the local pharmacy market as of January this year, ranking first. A Korean biotech venture that once relied on imported probiotic ingredients had turned the tables, capturing the specialist pharmacy distribution network in the heart of Europe. Lee Hyeon-yong, Cell Biotech's plant manager, said the vitality of Korean-origin strains gives the company an edge. "Koreans eat spicy, stimulating food, so our native strains have developed far greater resilience than Western strains by surviving in a harsh environment," Lee said. "Danish consumers tried our products themselves, experienced the intestinal delivery effect and the coating technology firsthand, and that is how we were able to break into the home market of probiotics." Cell Biotech currently supplies probiotics to 56 countries under its Duolac brand, with overseas sales now accounting for more than 50 percent of total revenue. A leading German multinational healthcare brand also sources finished products from the Gimpo production line. To keep pace with growing global demand, the company is reviewing a range of options, including expanding its production facilities. Beyond the traditional health supplement production wing, the company's next-generation growth engine — a microbiome-based biopharmaceutical line — stands ready for operation. A colorectal cancer drug candidate, PP-P8, engineered to secrete therapeutic proteins directly in the intestine using gene-editing technology, is advancing through a Phase 1 trial with Seoul National University Hospital, with researchers expecting positive results. Cell Biotech, a Korean probiotic production base that started three decades ago in a makeshift building in a rural valley, is now positioning itself for a leap into a global biopharmaceutical hub.
Nov. 10, 2026
-
K-small businesses ride export wave, with shipments up 56% and markets expanding
92 firms in global small business program post $7.06 million in exports Target markets grow from 44 to 75 countries, with 31 newly entered Six companies achieve first-ever exports; overseas market inroads widen Export deals worth 1.6 billion won shared at Jeju local startup festival Small businesses participating in a government export support program increased their overseas sales by more than 56 percent in a single year, while the number of destination markets expanded from 44 to 75 countries, the Ministry of SMEs and Startups said Monday. The ministry announced the findings after analyzing the export performance of 100 companies selected this year for its Global Small Business Development project. Of the 100 selected firms, the 92 with recorded export activity posted combined sales of $7.06 million through September, up 56.3 percent from $4.52 million last year. Export destinations grew from 44 countries to 75, as companies pushed beyond their traditional base in East Asia, the United States and China into Russia, Eastern Europe and Africa — entering 31 new markets in the process. Six companies that had no export record last year achieved their first overseas sales this year. One of them is Sameon, a South Chungcheong Province-based company that developed health snacks using byproducts from red ginseng production in Geumsan. The firm, which repurposes waste from the red ginseng manufacturing process, recorded roughly $11,000 in first-time exports this year and has been cited as a model for leveraging regional specialties. Cosmetics company Dermis, which uses functional ingredients derived from salmon, also sharply expanded its exports — from about $38,000 in 2024 to roughly $270,000 this year. Both companies were recognized at the K-Small Business Insight Day, held Friday in Jeju as part of the inaugural Local Startup Festa in Jeju. Sameon received a Ministry of SMEs and Startups Minister's Award in the Frontier category, while Dermis was honored in the Step-Up category. The Global Small Business Development project, introduced by the ministry for the first time this year, identifies small businesses in the consumer goods sector with strong export potential and supports their overseas expansion. The program provides step-by-step assistance — including export capacity training, export-ready product development and participation in overseas consumer goods trade fairs — and offers selected companies up to 100 million won ($73,600) in commercialization funding. The Local Startup Festa, held over three days in Jeju from Wednesday through Friday, also yielded export results. About 1,000 participants attended, including local companies, small business owners, investors and overseas buyers. Seven local firms shared news of export contracts totaling 1.6 billion won concluded at the event. Buyers from China and Hong Kong submitted letters of intent, signaling further cooperation ahead. The ministry said it plans to link the buyer consultations and business networking that took place at the event to follow-up support programs, with the aim of converting them into actual exports and investment. "As global interest in and enthusiasm for K-consumer goods continues to grow, we will provide full-scale support to help innovative small businesses bring their outstanding products to international markets," said Kim Jeong-ju, director general of the ministry's Small Business Policy Bureau.
Nov. 10, 2026
-
Korean home care medicine society holds 2026 fall academic conference in Seoul
'Treatment must continue outside the hospital' — home care medicine moves beyond expanding coverage toward quality reform; discussions range from broadening eligibility to younger patients to building outcome-based evaluation frameworks and strengthening care continuity from discharge to home As medical services extend from hospitals into the home, home care medicine policy is reaching a new turning point. Calls are growing to move beyond simply increasing the number of patients eligible for home visits and the institutions providing them, and instead to ensure that patients can receive safe, continuous treatment at home by securing quality care and service continuity. A key challenge raised at the conference was the need to move away from a system focused on elderly long-term care recipients and expand support to all age groups requiring medical care. The Korean Academy of Home Care Medicine held its 2026 fall academic conference Sunday at Hotel Samjeong in Gangnam-gu, Seoul, under the theme "Expanding to the Home, Setting the Standard: The Growth and Quality of Home Care Medicine." The conference was organized to pursue both the quantitative expansion and qualitative improvement of home care medicine at the same time. Experts from medicine, nursing, caregiving and health information fields took part, drawing on the experiences of patients and their families to discuss a broad range of topics — including frameworks for evaluating medical services, clinical management, post-discharge care coordination, health information sharing and the use of telemedicine. Discussion centered particularly on the need to move away from measuring home care outcomes by the number of visits or service delivery figures, and instead focus on substantive treatment results — including patients' health status, maintenance of daily life, and reductions in preventable hospitalizations and emergency room visits. Redefining quality benchmarks: outcomes over visit counts The first session, chaired by Board Chairman Park Geon-woo, examined the role of home care medicine and its evaluation criteria, starting from the realities of care as experienced by patients and their families. Cho Ki-hyun, an author and representative of the young caregivers community N-inbun, and Hong Jong-won, director of Geongangeui Jip Clinic, shared the difficulties and experiences that family caregivers and visiting physicians face in the field, drawing on their co-authored book "When We Call Our Relationship Care." Kim Ju-hyung, academic director of the Korean Academy of Home Care Medicine, Lee Jeong-seok, director of the Long-Term Care Research Center at the National Health Insurance Service, and Seo Hui-jeong, director of the Service Innovation Center at the Korea Institute for Healthcare Accreditation, then joined the discussion on institutional measures to objectively evaluate and guarantee the quality of home care medicine. Kim said quantitative indicators alone — such as the number of home visits and inter-institutional referrals — are insufficient to adequately assess the actual level of medical services provided. Kim proposed that evaluations should incorporate the appropriateness of treatment records, follow-up measures based on test results, medication management for patients taking multiple drugs simultaneously, and whether preventable hospitalizations and emergency room visits have occurred. Participants also called for strengthening the role of specialized home nursing and home rehabilitation institutions and building a cooperative framework with medical facilities. Emphasis was placed on developing a community-level coordination model that allows small clinics to participate in home care medicine, along with a division of roles that lets physicians focus on clinical care. From nutrition and dementia management to post-discharge care: strengthening treatment continuity The clinical session, chaired by Vice President Oh Dong-ho, addressed health management challenges frequently encountered in home care settings for patients with serious and chronic conditions. Lee Chung-hyung, the academy's education director and director of Seoul Bom United Clinic, explained the importance of home-based nutritional management, saying assessments should go beyond weight changes and food intake to comprehensively evaluate swallowing function, the patient's living environment and the family's caregiving capacity. Lee Sang-beom, the academy's administrative director and director of Seoul Sinnae Clinic, presented the need for tailored management of Alzheimer's patients that accounts for drug tolerability in elderly and underweight patients, gradual dose adjustment, polypharmacy and medication adherence. The nursing session, chaired by Vice President Tak Yeong-ran, focused on continuity of treatment from hospital to home as its central agenda. Kim Yun-ok, team leader at Asan Medical Center's Integrated Care Support Center, introduced "WithONE," an integrated care program for high-risk elderly patients. The program screens for frailty and functional decline from the early stages of hospitalization and connects patients to home nursing, home care medicine and community resources through multidisciplinary intervention and integrated discharge planning. Lee Yun-gyeong, a director at Bayada Home Health Care, drew on the organization's international home care accreditation experience to propose standardized guidelines covering patient safety, data protection, emergency response, caregiver education, and the communication of treatment and medication information. Japan's care system was also introduced. Seiko Adachi, vice president of Japan's Shinko Social Welfare Foundation and representative of Home Instead Japan, explained the role of care managers in linking medical and long-term care services, and said responsibilities by profession and information-sharing frameworks must be clearly defined. Bridging information gaps: digital technology and telemedicine in home care Participants said that for home care medicine to take root as a sustainable healthcare system, the information gaps between medical institutions must be resolved and a digital infrastructure usable in the field must be established. In the final session, chaired by President Lee Geon-se, Byeon Ji-hye of BITComputer and Kim Jeong-yun, development team leader at Wangjin Research Institute, shared their experiences building electronic medical record systems tailored to home visit care. They explained the need for a system that reduces duplicate documentation in home visit settings and allows physicians, nurses and other professionals to share patient information smoothly. Participants said that linking existing hospital EMR systems with home visit records would require standardizing common data fields, medical terminology, codes, information exchange formats and inter-institutional referral and response procedures. Jang Min-cheol, head of the PHR project division at the Korea Health Information Service, introduced the "Health Information Highway" and the medical MyData initiative, explaining a framework for securely linking and using medical information based on patients' own consent. Yoo Gyeong-ho, chairman of the Korean Society of Telemedicine, proposed a collaborative model that connects the on-site judgments of community primary care physicians and nursing staff to specialist consultations and hospital treatment, and then feeds post-emergency treatment outcomes back to local medical teams. The discussions focused on the idea that digital technology in home care medicine must go beyond a tool for administrative convenience and serve as a foundation supporting care continuity and patient safety. 'Beyond long-term care recipients': expanding home care medicine to all ages A central theme of the conference was expanding the scope of home care medicine. President Lee said the field must move away from its existing approach centered on elderly long-term care recipients and connect services based on medical need to younger patients, those under 65, and people who have not been certified for long-term care or have not applied for it. Lee also said it is important to actively identify people who are missing out on needed services because they are unaware that home visit care and home nursing programs exist. Participants called for broadening the range of service providers as well. They said a structure is needed in which not only community home visit clinics but also hospitals, tertiary hospitals and home nursing centers cooperate according to the patient's condition and stage of treatment. Emphasis was placed on the need for uninterrupted coordination between medical institutions and community care services to stably support patients' health management and daily life after discharge. Building safety and quality management frameworks to accompany the expansion of services was also identified as a key challenge — including inter-institutional medical information linkage, personal data protection, safety for patients and visiting staff, and the establishment of standardized training and service standards. The academy said it plans to broaden the base of participation among diverse medical institutions and professionals, review overseas home care medicine experiences — including Japan's — for applicability to the domestic environment, and strengthen cooperation among the government, relevant agencies and frontline service providers. The conference was significant in that it shifted the direction of home care medicine policy from "how many services are provided" to "how safely and continuously those who need care actually receive it." "The outcomes of home care medicine must be measured not only by the number of institutions and visits, but by whether people who need the service are actually receiving it and able to maintain their daily lives," President Lee said. "Ensuring that quantitative expansion is matched by minimum service capacity and shared standards is an important task for the academy."
Nov. 9, 2026
-
Lee Kun-hee pediatric cancer, rare disease initiative marks 5 years, benefiting over 37,000 patients
A 10-year project funded by a 300 billion won donation has expanded diagnosis and treatment infrastructure over five years Seoul National University Hospital establishes Korea's first standard treatment protocol for pediatric acute lymphoblastic leukemia; more than 20 previously unknown rare diseases identified Research projects grow from 7 to 190; 1,411 medical professionals at 185 institutions nationwide now participating Seoul National University Hospital's Support Project for Pediatric Cancer and Rare Diseases announced Monday that the Lee Kun-hee Pediatric Cancer and Rare Disease Overcoming Project — launched with a 300 billion won ($221 million) donation from the late Samsung Chairman Lee Kun-hee's family — had diagnosed 22,646 patients and treated 14,757 others through September this year. The project office also held an international symposium that day, bringing together domestic and foreign experts to share five years of research findings and chart the course for future international collaborative research. The project launched in April 2021, with Seoul National University Children's Hospital designated as the lead institution and the project office formally established the following month. It is scheduled to run for 10 years through 2030. Over the past five years, the project office has developed diagnostic and treatment technologies for pediatric cancers and rare diseases while expanding the infrastructure needed for patient diagnosis and research. In the field of pediatric cancer, the project produced Korea's first standard treatment protocol for pediatric acute lymphoblastic leukemia. Patients are classified into five risk groups to guide treatment strategy, and the protocol incorporates genomic analysis and next-generation sequencing-based minimal residual disease monitoring to support precision medicine. In rare diseases, researchers identified and diagnosed more than 20 previously unknown conditions. A nationwide rare disease diagnostic network was established so that regional hospitals can send specimens and genetic information to a central analysis center, which returns results within four to six weeks. Regional hub institutions are also being supported to access advanced genomic testing, and families of pediatric patients with rare genetic diseases receive genetic counseling and prenatal diagnosis support. More than 60 percent of Korea's pediatric solid tumor patients are now enrolled in STREAM, a precision medicine platform for pediatric solid cancers. The platform has enabled new diagnoses for patients who had previously gone undiagnosed and allowed existing diagnoses to be reclassified for more effective treatment. Seoul National University Hospital has also built an in-house GMP facility capable of manufacturing CAR-T cells on site, and through September this year the project had produced and supplied CAR-T cells to 21 pediatric patients. The nationwide research collaboration network has grown substantially. The project office has broadened its research base by working with medical institutions across the country through its cancer, rare disease, and joint research divisions. The number of research projects it supports rose from 7 in 2021 to 190 this year. As of September, 1,411 medical professionals at 185 institutions nationwide are participating, and the pediatric cancer and rare disease patient cohort now holds 57,030 registered data entries. This collaboration is a critical foundation for giving children with hard-to-diagnose and hard-to-treat cancers and rare diseases better access to care. Rare diseases take an average of 9.2 years to diagnose, and about 50 percent of patients are still never diagnosed. There are only 69 pediatric hematology-oncology specialists nationwide, and more than 70 percent of pediatric cancer patients living outside Seoul receive treatment in a region other than their own. The project office connects the capabilities of medical institutions and researchers across the country to widen the diagnostic base and create an environment in which children can receive appropriate diagnosis and treatment regardless of where they live. The symposium was held under the theme "Opening the Future of Pediatric Precision Medicine: Advanced Research in Pediatric Cancer and Rare Diseases." Eight domestic and foreign experts — including representatives from the International Agency for Research on Cancer and universities in the United States and United Kingdom — participated in two sessions covering genomics-based precision medicine for pediatric cancer, CAR-T therapy development, international cooperation for rare disease diagnosis, precision gene editing, patient-derived organoids, and digital pathology research. About 200 people attended. "Pediatric cancers and rare diseases present many challenges that individual research institutions cannot solve on their own, given the small number of patients per condition and the wide variety of characteristics involved," said Project Director Chae Jong-hee. "I hope this symposium will serve as an opportunity to share research findings and clinical experience among domestic and foreign experts, strengthen the foundation for international collaborative research, and chart the direction for the next five years." "The true value of medical research lies in improving patients' lives," said Hospital President Baek Nam-jong. "This project demonstrates the potential for a virtuous cycle in which a meaningful private donation supports medical research, and the results in turn contribute to the diagnosis and treatment of patients." "The late Chairman Lee Kun-hee's lifelong philosophy of 'respect for human beings' extended to care and love for all lives, and for children in particular," said Jang Seok-hun, president of Samsung's social contribution operations. "It is deeply meaningful to share the research achievements of these past years with researchers from Korea and abroad at today's symposium. I hope this event will create more hope and more treatment opportunities not only for pediatric cancer and rare disease patients in Korea, but for children around the world." The project office plans to expand its international cooperation network and advance treatment technologies including CAR-T therapy while strengthening a sustainable research foundation. It will also develop programs for early diagnosis and disease prevention — among them rapid genetic diagnosis for critically ill infants, neonatal genomic screening, prenatal diagnosis, and preimplantation genetic testing. The office also intends to translate research findings into clinical practice and health policy to broaden diagnosis and treatment opportunities for pediatric cancer and rare disease patients.
Nov. 9, 2026
-
Korea Federation of SMEs graduates 58 CEOs from 20th executive program
58 SME CEOs complete 7-month management, AI curriculum KBIZ AMP traces roots to 2008 SB-CEO School launch Recruitment for 21st cohort opens in December The Korea Federation of SMEs' executive education program, KBIZ AMP, has graduated its 20th cohort of 58 participants, bringing the total number of alumni to 1,149 since the program launched as the SB-CEO School in 2008. The Korea Federation of SMEs held the KBIZ AMP 20th cohort graduation ceremony Monday at KBIZ Hall in Yeouido, Seoul. About 80 people attended, including Korea Federation of SMEs Executive Vice President Oh Ki-woong, KBIZ AMP Alumni Association President Lee Sin-haeng, Senior Vice President Choi Kang-jin and the graduating participants. KBIZ AMP is an executive education program designed to strengthen the management capabilities of small and medium-sized enterprise CEOs and expand networking among business leaders. It was launched as the SB-CEO School during the tenure of former Korea Federation of SMEs Chairman Kim Ki-moon in 2008. This year's 20th cohort ran for seven months across four themes: leadership and communication, strategic thinking and convergence, management essentials, and the happy CEO. The program included 15 regular lectures as well as breakfast seminars, domestic and overseas workshops, and alumni networking events. The curriculum particularly addressed how the spread of AI is reshaping the business environment. Han Sang-ki, CEO of Tech Frontier, lectured on global technology trends and corporate strategy in the AI era, while Choi Jae-bung, a professor at Sungkyunkwan University, covered survival strategies for the AI age. Park Jeong-ho, a professor at Myongji University, addressed the global economic outlook and SME response strategies, and Jang Hang-bae, a professor at Chung-Ang University, examined technology protection strategies for small businesses in an era of technological competition. At the graduation ceremony, 12 outstanding participants were recognized based on their attendance and alumni activities. Kim Tae-eun, CEO of Jinyeong Color Solution, received a merit plaque in recognition of contributions as class president. The Korea Federation of SMEs chairman's award went to seven recipients: Ko Yun-gyeong, director at Yeongjin Asset; Kim Ji-hong, CEO of Bacon Design Studio; Kim Ji-hun, CEO of E&S; Kim Hye-suk, CEO of The Hanoi; Nam Eun-gyeong, division head at EM Infini; Son Mi-ja, executive director at A Plus Asset Advisor; and Chu Jae-ho, CEO of Hangang Engineering. The alumni association president's award went to four recipients: Kim Yun-sun, CEO of Sejeon Yegeon; Lee Nam-un, CEO of NFS; Jo Gil-ju, CEO of Tomatosystem; and Jeong Ung-gi, CEO of J4U Solution. "Thank you for participating so actively with a passion for learning even during difficult times," Oh Ki-woong, executive vice president of the Korea Federation of SMEs, said. "Even after graduation, I hope you will strengthen your network through alumni association activities and help build a new future for AMP." The Korea Federation of SMEs plans to begin recruiting participants for the 21st cohort of KBIZ AMP in December.
Nov. 9, 2026
- 1Malaysia's BE International brings 1,500-strong incentive tour to Korea, bypassing Turkey
- 2AI singer tops Melon chart for first time with 'Did You Become the Adult You Dreamed Of?'
- 3Jensen Huang's daughter took the photo of him embracing his alleged mistress
- 4Man beat live-in girlfriend 514 times over 3 hours, killing her; forensic expert says footage was too disturbing to watch
- 5Crosswalk at Cheonggyecheon 6-ga intersection opens after 20 years of resident demands
- 6'A concert is a ritual for the soul': Currentzis makes long-awaited Korea debut after six years
-
WORLD
US warns of punishment for anyone enabling Iran's Strait of Hormuz toll scheme
-
INDUSTRY
Toyota union puts productivity first; Hyundai Motor union demands bigger share of profits
-
FINANCE
National Growth Fund to invest $531M in FuriosaAI, which rebuffed Meta's $800M takeover bid
-
INDUSTRY
Korea Shipowners' Association holds amateur baduk tournament for Maritime Day
